Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654064 | 0.98 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2653395 | 0.98 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2655129 | 0.98 | POLB (0.49) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2653067 | 0.95 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2653869 | 0.89 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL20772045 | 0.87 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL20772406 | 0.85 | POLB (0.48) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL5736276 | 0.84 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC6POLB | |
| SCHEMBL2162982 | 0.84 | HPGD (0.55) | POLBTDP1HPGDALDH1A1LMNA | |
| SCHEMBL6981207 | 0.83 | HPGD (0.57) | POLBTDP1HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2023-03-23 | — | — | US | disclosed |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY | 2021-02-18 | — | — | US | disclosed |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3675864-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | Duquesne University of The Holy Spirit (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190100524-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-04-04 | — | — | US | disclosed |
| WO-2019046612-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-1957484-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1856090-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007120284-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | HDAC3 825/4885HDAC4 1605/4885HDAC1 1304/4885 |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | MTHFD1, SHMT1, SHMT2 | HDAC3 825/4885HDAC4 1605/4885HDAC1 1304/4885 |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | HDAC3 962/4885HDAC4 1765/4885HDAC1 1494/4885 |
| US-20190100524-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | SHMT2, MTHFD1, SHMT1 | HDAC3 913/4885HDAC4 1930/4885HDAC1 1104/4885 |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | SHMT2, MTHFD1, SHMT1 | HDAC3 913/4885HDAC4 1930/4885HDAC1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.